Homology Medicines Inc (NASDAQ:FIXX) Director Kush Parmar sold 615,000 shares of the stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $21.47, for a total transaction of $13,204,050.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

FIXX opened at $22.13 on Tuesday. The firm has a market cap of $976.86 million, a price-to-earnings ratio of -11.07 and a beta of 0.11. Homology Medicines Inc has a 52-week low of $15.07 and a 52-week high of $31.80.

Homology Medicines (NASDAQ:FIXX) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by ($0.11). The company had revenue of $0.27 million for the quarter, compared to analysts’ expectations of $1.00 million. Homology Medicines had a negative net margin of 2,253.08% and a negative return on equity of 34.90%. As a group, equities research analysts predict that Homology Medicines Inc will post -2.28 EPS for the current year.

Several equities analysts have issued reports on the stock. Evercore ISI assumed coverage on shares of Homology Medicines in a report on Thursday, April 11th. They set an “outperform” rating and a $29.00 price objective on the stock. Zacks Investment Research raised shares of Homology Medicines from a “sell” rating to a “hold” rating and set a $25.00 price objective on the stock in a report on Thursday, May 9th. ValuEngine downgraded shares of Homology Medicines from a “buy” rating to a “hold” rating in a report on Friday, April 19th. Finally, HC Wainwright assumed coverage on shares of Homology Medicines in a report on Wednesday, February 20th. They set a “buy” rating and a $36.00 price objective on the stock. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $29.10.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. lifted its holdings in Homology Medicines by 29.7% during the third quarter. JPMorgan Chase & Co. now owns 2,251,444 shares of the company’s stock valued at $51,468,000 after purchasing an additional 516,156 shares in the last quarter. RTW Investments LP lifted its stake in shares of Homology Medicines by 275.6% in the fourth quarter. RTW Investments LP now owns 1,633,491 shares of the company’s stock worth $36,525,000 after buying an additional 1,198,574 shares in the last quarter. BlackRock Inc. lifted its stake in shares of Homology Medicines by 134.3% in the fourth quarter. BlackRock Inc. now owns 1,460,449 shares of the company’s stock worth $32,656,000 after buying an additional 837,099 shares in the last quarter. VV Manager LLC purchased a new position in shares of Homology Medicines in the fourth quarter worth about $17,236,000. Finally, Vanguard Group Inc lifted its stake in shares of Homology Medicines by 0.7% in the third quarter. Vanguard Group Inc now owns 473,945 shares of the company’s stock worth $10,834,000 after buying an additional 3,504 shares in the last quarter. 52.37% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.thecerbatgem.com/2019/05/21/insider-selling-homology-medicines-inc-fixx-director-sells-615000-shares-of-stock.html.

About Homology Medicines

Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

Featured Story: Return On Assets

Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.